Pure Global AI
NCT06120725Recruiting

Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke

Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke, a Randomized Controlled Trial
Kafrelsheikh UniversityPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Ischemic Stroke
Drug/Device/Intervention
Ticagrelor 90 MG
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Kafrelsheikh University
Location
Kafr Ash Shaykh, Egypt
Timeline & enrollment
Phase
Phase 3
Start date
Sep 01, 2021
End date
Nov 05, 2023
Enrollment
580 participants
Primary outcome

Rate of Hemorrhagic transformation of the Infarct,Rate of Peripheral Bleeding using PLATO classification,rate of drug adverse effects

Summary

Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of
 ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared
 to 300 mg clopidogrel were assessed through NIHSS, mRS, duration of hospital stay, and
 possible adverse effects.

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedOther cerebral infarction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06120725
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06120725 through Pure Global AI's free database. This Phase 3 trial is sponsored by Kafrelsheikh University and is currently Recruiting. The study focuses on Ischemic Stroke. Target enrollment is 580 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.